6 completed, 5 recruiting, 4 unknown, 3 active not recruiting. 21 Phase 2, 7 Phase 1, 2 Phase 3.
Follow PLD: new trials by email Literature Review of PLD trials Research Report on PLD
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Trial of NP-G2-044 (Prilukae) Combined With PLD for Treatment of Platinum-Resistant Ovarian Cancer (ULTIMUS-1) NP-G2-044, PLD - Platinum-resistant Ovarian Cancer | Phase 2 / Phase 3 | Active not recruiting | Novita Pharmaceuticals, Inc. | 380 | 2025-12-29 | 2026-03-09 |
| Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer Ubamatamab, Bevacizumab, Cemiplimab - Ovarian Cancer, Fallopian Tube Cancer | Phase 2 | Recruiting | Regeneron Pharmaceuticals | 297 | 2025-05-28 | 2026-09-14 |
| A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003). Raludotatug Deruxtecan, Carboplatin, Paclitaxel - Ovarian Cancer Recurrent | Phase 1 / Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 605 | 2025-04-15 | 2026-10-30 |
| A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma Golcadomide, Rituximab, Cyclophosphamide - Lymphoma, Follicular | Phase 2 | Active not recruiting | Celgene | 95 | 2024-08-30 | 2026-07-31 |
| A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer R-DXd, Paclitaxel, Topotecan - Solid Cancer | Phase 2 / Phase 3 | Recruiting | Daiichi Sankyo | 860 | 2024-02-27 | 2026-10-26 |
| IN10018 in Combination With Pegylated Liposomal Doxorubicin (PLD) vs. Placebo in Combination With PLD for the Treatment of Platinum-resistant Recurrent Ovarian Cancer IN10018, Placebo of IN10018, Pegylated Liposomal Doxorubicin - Ovarian Cancer Recurrent | Phase 2 | Recruiting | InxMed (Shanghai) Co., Ltd. | 168 | 2022-09-06 | 2025-04-30 |
| The Effectiveness and Safety of XELOX and Tislelizumab + PLD for Resectable Gastric Cancer (LidingStudy) PLD, Oxaliplatin, Capecitabine - Gastric Cancer | Phase 2 | Recruiting | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 38 | 2022-09-05 | 2023-03-09 |
| Study of Maplirpacept (PF-07901801) in Combination With PLD in Patients With Platinum-Resistant Ovarian Cancer maplirpacept (PF-07901801), Pegylated Liposomal Doxorubicin (PLD) - Ovarian Cancer, Ovarian Neoplasms | Phase 1 / Phase 2 | Terminated | Pfizer | 10 | 2022-08-01 | 2024-11-19 |
| Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a) and Pegylated Liposomal Doxorubicin (Phase 1b) as Treatment for Ovarian Cancer. TILT-123, pembrolizumab, pegylated liposomal doxorubicin - Platinum-refractory Ovarian Carcinoma, Platinum-resistant Ovarian Cancer | Phase 1 / Phase 2 | Active not recruiting | TILT Biotherapeutics Ltd. | 29 | 2022-05-17 | 2026-05-05 |
| Efficacy and Safety of SG001 Combined With PLD in Patients With Platinum-resistant Relapsed EOC SG001, Doxorubicin hydrochloride liposome injection - Epithelial Ovarian Cancer, Fallopian Tube Cancer | Phase 2 | Unknown | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 126 | 2021-09-01 | 2021-07-30 |
| ATG-010(Selinexor) in Combination With Chemotherapy in RRMM Selinexor (80mg/d), Selinexor (100mg/d), Pegylated liposomal doxorubicin - Multiple Myeloma | Phase 2 | Unknown | Chunyan Sun, MD | 50 | 2021-05-21 | 2023-12-06 |
| A Clinical Trial to Evaluate AZD7648 Alone and in Combination With Other Anti-cancer Agents in Patients With Advanced Cancers. AZD7648, PLD - Advanced Malignancies | Phase 1 / Phase 2 | Completed | AstraZeneca | 30 | 2019-10-09 | 2024-02-06 |
| ACHP-THP vs EC-THP as Neoadjuvant Therapy for HER2-positive EBC Doxorubicin liposome, Cyclophosphamide, Trastuzumab - Breast Cancer, Neoadjuvant Chemotherapy | Phase 2 | Unknown | Sun Yat-sen University | 156 | 2019-01-10 | 2023-10-16 |
| Resistant Ovarian Cancer, Olaparib and Liposomal Doxorubicin Olaparib, Pegylated Liposomal Doxorubicin - Advanced Ovarian Cancer | Phase 2 | Completed | Grupo Español de Investigación en Cáncer de Ovario | 32 | 2017-12-13 | 2023-01-27 |
| PLD Combined With Cisplatin in the Treatment of Advanced Poorly Differentiated Thyroid Carcinoma PLD, Cisplatin - Poorly Differentiated Thyroid Carcinoma | Phase 2 | Unknown | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 30 | 2017-03-06 | 2018-01-03 |
| Phase 1/2 Study of Motolimod, Doxorubicin, and Durvalumab in Recurrent, Platinum-Resistant Ovarian Cancer Durvalumab, Pegylated Liposomal Doxorubicin, Motolimod - Ovarian Cancer | Phase 1 / Phase 2 | Completed | Ludwig Institute for Cancer Research | 53 | 2015-12-02 | 2022-10-10 |
| Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Adavosertib, Paclitaxel, Carboplatin - Ovarian, Fallopian Tube, Peritoneal Cancer, P53 Mutation | Phase 2 | Completed | AstraZeneca | 95 | 2015-01-30 | 2023-10-03 |
| Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients Melphalan, Prednisone, Cyclophosphamide - Multiple Myeloma | Phase 1 / Phase 2 | Completed | Oncotherapeutics | 45 | 2014-09-01 | 2023-10-31 |
| Pomalidomide for Lenalidomide for Relapsed or Refractory Multiple Myeloma Patients POM, Steroids, PLD - Multiple Myeloma | Phase 2 | Terminated | Oncotherapeutics | 45 | 2014-07-07 | 2023-11-03 |
| A Study of DNIB0600A in Comparison With Pegylated Liposomal Doxorubicin (PLD) in Participants With Platinum-Resistant Ovarian Cancer (PROC) DNIB0600A, PLD - Ovarian Cancer | Phase 2 | Terminated | Genentech, Inc. | 95 | 2014-02-06 | 2017-08-21 |
Showing 20 of 21. Sign in to see all of them.
Ovarian Neoplasms (6) · Fallopian Tube Neoplasms (4) · Multiple Myeloma (4) · Carcinoma, Ovarian Epithelial (2) · Adenoviridae Infections (1) · Breast Neoplasms (1) · Hematologic Neoplasms (1) · Lymphoma (1) · Lymphoma, Follicular (1) · Recurrence (1) · Stomach Neoplasms (1)
AstraZeneca (2) · CSPC ZhongQi Pharmaceutical Technology Co., Ltd. (2) · Oncotherapeutics (2) · Celgene (1) · Chunyan Sun, MD (1) · Daiichi Sankyo (1) · Genentech, Inc. (1) · Grupo Español de Investigación en Cáncer de Ovario (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · InxMed (Shanghai) Co., Ltd. (1) · Ludwig Institute for Cancer Research (1) · Merck Sharp & Dohme LLC (1) · Novita Pharmaceuticals, Inc. (1) · Pfizer (1) · Regeneron Pharmaceuticals (1)
United States (14) · Canada (6) · China (6) · Spain (5) · United Kingdom (5) · South Korea (4) · Taiwan (4) · Australia (3) · France (3) · Poland (3) · Brazil (2) · Finland (2) · Germany (2) · Italy (2) · Switzerland (2)
James R Berenson, MD (2) · Bradley J Monk, MD (1) · Chunyan Sun, M.D., Ph.D (1) · Dr Timothy Yap (1) · George Coukos, MD, PhD (1) · Jillian Zhang, PhD (1) · Kathleen Moore, MD (1) · Lingying WU (1) · Lisa Barroilhet, MD (1)
PMID 29401246, PMID 31851518, PMID 34329939, PMID 34645648, PMID 37407274, PMID 39506856, PMID 41566775
2015 (1), 2016 (1), 2018 (1)